Tarsus Pharmaceuticals (TARS) Receivables - Other (2019 - 2026)

Tarsus Pharmaceuticals' Receivables - Other history runs 8 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 876.43% year-over-year to $16.9 million in Q1 2026; TTM through Mar 2026 was $16.9 million, a 876.43% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, up 57.97% from the prior year.
• Receivables - Other rose to $16.9 million in Q1 2026 per TARS's latest filing, from $336000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $16.9 million in Q1 2026 and bottomed at -$3.2 million in Q1 2023.
• The 5-year median for Receivables - Other is $1.1 million (2024), against an average of $1.9 million.
• Across the five-year window, Receivables - Other surged 7886.96% in 2022 and sank 1134.31% in 2023, its largest moves.
• Year by year, Receivables - Other stood at $3.6 million in 2022, then sank by 97.65% to $84000.0 in 2023, then soared by 83.33% to $154000.0 in 2024, then soared by 118.18% to $336000.0 in 2025, then surged by 4918.75% to $16.9 million in 2026.
• Per Business Quant, the three latest TARS Receivables - Other figures stand at $16.9 million (Q1 2026), $336000.0 (Q4 2025), and $1.7 million (Q3 2025).